Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. News
Jul 10, 2025 - globenewswire.com
Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference
Jun 5, 2025 - globenewswire.com
Cocrystal Pharma's Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference
May 29, 2025 - globenewswire.com
Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain
May 28, 2025 - globenewswire.com
Cocrystal Pharma to Participate in Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference
Cocrystal Pharma, Inc. Quantitative Score
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.
Cocrystal Pharma, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Cocrystal Pharma, Inc. Financials
Table Compare
Compare COCP metrics with: | |||
|---|---|---|---|
Earnings & Growth | COCP | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | COCP | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | COCP | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | COCP | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Cocrystal Pharma, Inc. Income
Cocrystal Pharma, Inc. Balance Sheet
Cocrystal Pharma, Inc. Cash Flow
Cocrystal Pharma, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Neutral |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Cocrystal Pharma, Inc. Executives
| Name | Role |
|---|---|
| Mr. James J. Martin CPA, M.B.A. | Co-Chief Executive Officer, Chief Financial Officer & Corporate Secretary |
| Dr. Sam Lee Ph.D. | Co-Founder, Co-Chief Executive Officer & President |
| Dr. Roger D. Kornberg Ph.D. | Co-Founder, Independent Chairman, Chief Scientist & Chairman of Scientific Advisory Board |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. James J. Martin CPA, M.B.A. | Co-Chief Executive Officer, Chief Financial Officer & Corporate Secretary | Male | 1967 | 610.46K |
| Dr. Sam Lee Ph.D. | Co-Founder, Co-Chief Executive Officer & President | 1960 | 610.46K | |
| Dr. Roger D. Kornberg Ph.D. | Co-Founder, Independent Chairman, Chief Scientist & Chairman of Scientific Advisory Board | 1947 | 160.5K |
Cocrystal Pharma, Inc. Insider Trades
| Date | 9 Oct |
| Name | Kornberg Roger D. |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 28109 |
| Date | 9 Oct |
| Name | FROST PHILLIP MD ET AL |
| Role | Director, 10 percent owner |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 27100 |
| Date | 9 Oct |
| Name | Rubin Steven D |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 18957 |
| Date | 9 Oct |
| Name | Lee Sam |
| Role | President and Co-CEO |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 40000 |
| Date | 9 Oct |
| Name | PFENNIGER RICHARD C JR |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 8067 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 9 Oct | Kornberg Roger D. | Director | Acquired | A-Award | 28109 |
| 9 Oct | FROST PHILLIP MD ET AL | Director, 10 percent owner | Acquired | A-Award | 27100 |
| 9 Oct | Rubin Steven D | Director | Acquired | A-Award | 18957 |
| 9 Oct | Lee Sam | President and Co-CEO | Acquired | A-Award | 40000 |
| 9 Oct | PFENNIGER RICHARD C JR | Director | Acquired | A-Award | 8067 |